



Nayak, A., Akpunarlieva, S., Barrett, M. and Burchmore, R. (2018) A defined medium for Leishmania culture allows definition of essential amino acids. *Experimental Parasitology*, 185, pp. 39-52. (doi:10.1016/j.exppara.2018.01.009)

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/156083/>

Deposited on: 2 February 2018

Enlighten – Research publications by members of the University of Glasgow
<http://eprints.gla.ac.uk>

A defined medium for *Leishmania* culture allows definition of essential amino acids

Archana Nayak, Snezhana Akpunarlieva, Michael Barrett, Richard Burchmore

Institute of Infection, Immunity and Inflammation and Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

Abstract

Axenic culture of *Leishmania* is generally performed in rich, serum-supplemented media which sustain robust growth over multiple passages. The use of such undefined media, however, obscures proteomic analyses and confounds the study of metabolism. We have established a simple, defined culture medium that supports the sustained growth of promastigotes over multiple passages and which yields parasites that have similar infectivity to macrophages to parasites grown in a conventional semi-defined medium. We have exploited this medium to investigate the amino acid requirements of promastigotes in culture and have found that phenylalanine and tryptophan are essential for viability in culture, while the absence of arginine, leucine, lysine, and valine results in significantly impaired, almost negligible growth. Most of the 20 proteogenic amino acids promote growth of *Leishmania* promastigotes, with the exception of alanine, asparagine, and glycine. This defined medium will be useful for further studies of promastigote substrate requirements, and will facilitate future proteomic and metabolomic analyses.

Introduction

Leishmania parasites cause a spectrum of important diseases in animals, including humans, which are collectively termed leishmaniasis. *Leishmania* have a digenetic life-cycle that involves an alternation between two distinct forms, promastigotes and amastigotes, and a transmission between two hosts, an invertebrate and a vertebrate host. While it is possible to study *Leishmania* biology in insect and mammalian host models, there are significant advantages to studying parasites in axenic culture, in particular the possibility to generate large quantities of uncontaminated parasite material under controlled conditions. However, the nutrient media that are routinely employed for axenic cell culture contain a variety of carbon sources and are typically supplemented with undefined animal sera. Such rich, serum-supplemented media may elicit phenotypes that differ from those which prevail in the nutritionally-sparse environments that the parasites encounter in the sand fly gut and the macrophage phagolysosome. Furthermore, the presence of undefined components in the culture media complicates the interpretation of biochemical data, and is a particular problem for proteomic and metabolomic studies, since heterologous proteins may obscure the characterisation of the parasite proteins of interest and the provenance of metabolites is unknown. The addition of undefined sera to culture media has specific safety implications for the production of tools such as vaccines.

A variety of media for growing *Leishmania* promastigotes have previously been reported (Table 1) [1 - 32], but the addition of either serum or protein has been necessary to support continuous growth over multiple passages. Many of the earlier media, such as the Novy-MacNeal-Nicolle (NNN) [9] and LIT-R9 [18], contain complex, undefined additions such as blood components or infusion from brain or liver [11, 12]. Such components can be substituted with peptone and yeast extracts, in media such as PY A-FBS 10 [17], Y-P [21], AJM-1 [22], and CML [27] (Table 1), or by the addition of animal serum. Work by Trager [10], Steiger and Steiger [13, 14], and Berens [15] established that animal serum could be replaced by bovine albumin for *in vitro* culture of *Leishmania*, resulting in the development of simplified yet still incompletely defined culture media.

Alternative medium formulations have also included components such as urine [19, 23], casein hydrolysate [22], and lemon extract [29]. These additions are less costly than animal sera but, like serum, are undefined and potentially variable. Trager [10] and Steiger and Black [33] were the first to report chemically defined, serum- and protein-free media that were able to support growth of *Leishmania* species (Table 1). Subsequent publications have expanded the number of media with a more completely defined composition (Table 1) [34 - 37], including the more recent work of Fritsche *et al.* [28] and Merlen *et al.* [38]. SFP medium [28] is supplemented with protein and RNA and CDM/LP medium [38] has an elaborate composition, including cholesterol.

We thus set out to develop a completely defined, synthetic medium able to support continuous growth of *Leishmania* promastigotes in axenic culture. As a foundation, we used the most simplified medium developed by Steiger and Black [33], then omitted components that were not chemically defined and systematically modified the composition to determine the relative importance of amino acids, co-factors, vitamins, and metals. This led to the development of a defined medium, termed Nayak Medium (NM) which supports continuous growth of *L. mexicana* promastigotes. We observed that the kinetics of *L. mexicana* promastigote growth in NM medium approach those seen in a conventional rich, serum-supplemented medium, and that the promastigote morphology and infectivity to macrophages are similar to cells grown in a conventional media.

Table 1. Media proposed for culture of *Leishmania*.

| | Media | Composition | Reference |
|--|--------------------------------------|---|--|
| Serum- and/or protein-supplemented media | M199 | Supplemented with 5% serum | Morgan <i>et al.</i> , 1950 |
| | DMEM | Supplemented with 10% serum | Dulbecco and Freeman, 1959 |
| | RPMI 1640 | Supplemented with 10% serum | Moore <i>et al.</i> , 1967 |
| | Grace's insect tissue-culture medium | Supplemented with 20% serum | Grace, 1962; Childs <i>et al.</i> , 1978 |
| | Mitsuhashi-Maramorsch medium | Supplemented with 20% serum | Mitsuhashi and Maramorsch, 1964; Childs <i>et al.</i> , 1978 |
| | HOMEM | Supplemented with 20% serum | Berens <i>et al.</i> , 1976 |
| | Schneider's <i>Drosophila</i> medium | Supplemented with (30%) serum | Schneider, 1972 |
| | NNN | Contains blood agar and 0.6% NaCl | Nicolle, 1908 |
| | Medium S | Supplemented with bovine plasma fraction V | Trager, 1957 |
| | GLSH | Contains glucose, lactalbumin, hemoglobin, supplemented with 10% serum | Jardin and Le Ray, 1969 |
| | -- | Contains rabbit blood lysate, beef and liver infusion, salts, and glucose | Dwyer, 1972 |
| | RE I | Contains minimal number of components, including bovine albumin | Steiger and Steiger, 1976 |
| | RE III | Simplified RE I | Steiger and Steiger, 1977 |
| | HOSMEM-II | MEM-based, supplemented with bovine albumin fraction IV | Berens and Marr, 1978; Schuster and Sullivan, 2002 |
| | PYA-FBS 10 | Contains peptone, yeast autolysate, salts, supplemented with 10% serum | Palomino, 1982 |
| | LIT-R9 | Contains liver infusion and tryptose | Sadigursky and Brodskyn, 1986 |
| | -- | M199 supplemented with urine | Armstrong and Patterson, 1994 |
| | -- | Contains bovine hemoglobin powder | Agarwal and Jain, 1996 |
| | P-Y | Contains peptone, yeast extract, salts, supplemented with 10% serum | Limoncu <i>et al.</i> , 1997 |
| | AJM-1 | Contains peptone, casein hydrolysate, beef and yeast extracts | Ali <i>et al.</i> , 1998 |
| | -- | M199 supplemented with 10% human urine | Singh <i>et al.</i> , 2000 |
| | -- | Contains Brain Heart Infusion (BHI), supplemented with hemin | Meehan <i>et al.</i> , 2000 |
| | cRPMI | RPMI 1640 supplemented with filtered and dialyzed, protein- and low molecular weight component-free serum fractions | Santarem <i>et al.</i> , 2003 |
| | -- | M199 supplemented with cow, buffalo, or goat milk | Muniaraj <i>et al.</i> , 2007 |
| | CML | Supplemented with peptone and yeast extract | Sharief <i>et al.</i> , 2008 |
| | SFP | Supplemented with BSA (SFP(I)), BSA and hemin (SFP(II)), PEG-hemin (SFP(III)) | Fritsche <i>et al.</i> , 2008 |
| | GALF-1 | Contains minimal number of components, lemon extract, 2% urine, and 20% serum | Tasew <i>et al.</i> , 2009 |
| | PBHIL | Contains glucose, salts, peptone, BHI, liver infusion broth, and hemin | Rodrigues <i>et al.</i> , 2010 |
| | SNB-9 | Contains blood agar, neopeptone, and 0.6% NaCl | Grekov <i>et al.</i> , 2011 |
| | -- | Contains nutrient agar, nutrient broth, and 10% serum | Aksoy Gokmen <i>et al.</i> , 2015 |
| Serum- and/or protein-free media | Medium C | Contains minimal number of components | Trager, 1957 |
| | RE IX | Simplified RE III, lacks bovine albumin | Steiger and Black, 1980 |
| | RE X | RE IX without glucose | |
| | MD29 | Contains a variety of purines and pyrimidines | Melo <i>et al.</i> , 1985 |
| | -- | Rich in nutrients | O'Daly and Rodriguez, 1988 |
| | S- α -MEM | α -MEM and RPMI 1640 supplemented with hemin, HEPES, glutamine, glucose, folic acid, biotin, and adenine | Kar <i>et al.</i> , 1990 |
| | S-RPMI | | |
| | -- | M199 supplemented with HEPES, co-factors, and vitamins | McCarthy-Burke <i>et al.</i> , 1991 |
| | CDM/LP | Contains complex fatty acids and amino acid intermediates | Merlen <i>et al.</i> , 1999 |

Experimental procedures

Cell culture

Leishmania mexicana MNYC/BZ/62/M379, *L. donovani* MHOM/SD/63/Khartoum, and *L. major* MHOM/IL/80/Friedlin were passaged at an initial density of 5.0×10^5 cells/mL in hemoflagellate-modified minimum essential medium (HOMEM) [7] (Invitrogen, Thermo Fisher Scientific) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) (Biosera), and cultured at 27°C. Viability and integrity of the cells was assessed using the trypan blue dye (Sigma-Aldrich, Merck) exclusion test [39]. Parasite growth was followed by diluting a 0.01 mL aliquot of the cell culture with 2% (w/v) formaldehyde-phosphate buffered saline (PBS) (Sigma-Aldrich, Merck) and counting the cells on an improved Neubauer haemocytometer.

Medium preparation

Based on Steiger and Black's RE IX medium [33] and the nutrient requirements of *Leishmania* promastigotes determined in this study, a base medium (BM) and an optimised defined medium (NM) were developed. Compound stock solutions were prepared by dissolving individual components (Sigma-Aldrich, Merck) in Milli-Q water, except adenosine, biopterin, folic acid, hemin, and lipoic acid which were dissolved in 1N NaOH. The stock solutions were then filter sterilized through 0.22 μm Express PLUS membrane filters (Millipore, Merck) and stored in aliquots at -20°C. The pH of all media was adjusted to 7.4 and the media were also filter sterilized.

Estimation of nutrient requirements

To assess amino acid requirements, 1.0×10^6 cells/mL log phase promastigotes grown in HOMEM were harvested by centrifugation at $1000 \times g$ for 10 min at room temperature (RT), then the pellets were washed with NM lacking amino acids (NM-AA) and re-suspended in Nayak single amino acid "knock out" media, containing all amino acids bar one.

To assess metal and cofactor requirements, 1.0×10^6 cells/mL log-phase promastigotes grown in HOMEM were harvested by centrifugation at $1000 \times g$ for 10 min at RT, then the pellets were washed twice with BM and re-suspended in BM supplemented with cocktails of co-factors and metals (Sigma-Aldrich, Merck). The co-factor cocktail contained 10 μM of biopterin, lipoic acid, and the vitamins biotin, folic acid, and riboflavin. Hemin was not included in the tested cocktail. The metal cocktail included magnesium, calcium, zinc, iron, cobalt, copper, and manganese.

The growth data presented comprise representative information from 5 independent assays, each carried out in triplicate (n=15). All data were analysed using one-way Analysis of Variance (ANOVA) with Dunnett's multiple comparison test and a significance threshold of $p < 0.0001$ (Graph-pad Prism software). Images of cells cultured in the single amino acid "knock out" medium were prepared by smearing 200 μL of culture medium from each condition onto glass slides (Marienfeld). The slides were then air-dried and the cells fixed by

dipping the slides into ice cold methanol for 2 min. The slides were air-dried again and stained with Giemsa (Sigma-Aldrich, Merck) (diluted in 10mM phosphate buffer, pH 7.2) for 20 min. Dried slides were visualised using light microscopy (Axiovision,) and the images analysed by Fiji-Image J software, with a standard scale bar of 10µm assigned for a constant number of pixels. 50 cells from each slide were measured and cell body length plotted as their frequency distribution. For statistical significance, one-way ANOVA was performed with Dunnett's multiple comparison test.

Estimation of protein concentration

1.0×10^7 cells in total, grown in single amino acid "knock out" media, were harvested by centrifugation at 1000 x g for 10 min at RT, re-suspended in PBS containing 0.05% Triton X100, 5% glycerol, 2mM 1,10-phenanthroline, 10µM leupeptin, 7µM pepstatin, and 10µM E64 (Sigma-Aldrich, Merck) and lysed by sonication. Protein concentration was determined by Bradford assay (Bio-Rad). Data were derived from three independent experiments, each performed in triplicate (n=9).

Estimation of infectivity

THP1 cells were cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific) supplemented with 10% FCS at 37°C and 5% CO₂. Cultures were initiated at a density of 5.0×10^5 cells/mL and sub-passaged every five days. THP1 cells were differentiated using 100nM phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, Merck) and plated on Nunc Lab-Tek Chamber slides (Sigma-Aldrich, Merck) 24 h prior to infection. After a four-hour incubation, *L. mexicana* promastigotes, cultured in either HOMEM or NM to stationary phase, and heat-killed parasites were collected by centrifugation at 1000 x g for 10 min at RT, then resuspended in RPMI 1640 medium, and added to THP1 cells at a 1:10 ratio. The chamber slides were incubated for 4 h at 32°C and 5% CO₂, then the medium replaced to removed extracellular promastigotes. At intervals of 4, 24, 48, 96 and 144 h post-infection, THP1 cells were washed three times with PBS, fixed by immersion in ice cold methanol and stained with Giemsa for 20 min as described above. Dried slides were visualised using light microscopy (AxioVision, Zeiss) and the percentage of infectivity and number of amastigotes per macrophage calculated.

Estimation of drug sensitivity

Alamar blue assay was used to assess the IC_{50s} of three leishmanicidal compounds as described by Raz *et al.* [40]. Briefly, 1.0×10^6 cells/mL were diluted in either HOMEM or NM media and 5.0×10^5 cells/mL were inoculated into 96-well flat-bottomed microtiter plates (Sigma-Aldrich, Merck) and incubated for 72 h at 27°C with amphotericin B, pentamidine, and methotrexate (Sigma-Aldrich, Merck). The latter were diluted in either HOMEM or NM media, in a 8-fold dilution series that covered a range from 200µM to 0.2µM. Then 0.49mM of the fluorescent dye resazurin (Sigma-Aldrich, Merck) was added to each cell suspension and the incubation was continued for further 48 h. Fluorescence was measured on a PHERAstar FS spectrometer (BMG Labtech) at excitation and emission wavelength of 544 nm and 590 nm, respectively. Regression analysis was used to determine

the IC₅₀ of the compounds. The data were log transformed and sigmoidal dose-inhibition curves plotted using GraphPad Prism. Data were derived from three independent experiments, each performed in duplicate (n=6).

Results

Development of defined media for axenic culture of *Leishmania* promastigotes

We have developed a serum- and protein-free medium with a simple, defined composition. As a reference point, we supplemented a previously reported growth medium, RE IX [33], to produce an amino acid-rich basal medium (BM) (Table 2), in which we performed nutrient requirement analyses. These experiments led to the development of Nayak medium (NM) (Table 2), which is able to support continuous culture of *L. mexicana* promastigotes at a growth rate comparable to that of cells grown in conventional rich, serum-supplemented media such as HOMEM [7]. By systematically modifying NM, we investigated the importance of individual amino acids for sustaining *L. mexicana* promastigote growth.

Table 2. Composition of base medium (BM) and Nayak medium (NM) for axenic culture of *Leishmania* promastigotes. *, present in the media but not in the co-factor cocktail.

| Components | BM (concentration, mM) | NM (concentration, mM) |
|---|---------------------------|---------------------------|
| Salts | | |
| KCl | 5.36 | 5.36 |
| NaCl | 136.8 | 136.8 |
| NaH ₂ PO ₄ | 0.33 | 0.33 |
| NaHCO ₃ | 3.57 | 3.57 |
| Vitamins | | |
| Biotin | - | 0.01 |
| D-Calcium pantothenate | 0.002 | 0.002 |
| Folic acid | 0.002 | 0.012 |
| Nicotinamide | 0.008 | 0.008 |
| Pyridoxal HCl | 0.004 | 0.004 |
| Riboflavin | 0.002 | 0.012 |
| Thiamine HCl | 0.002 | 0.002 |
| Co-factors | | |
| <i>p</i> -Aminobenzoic acid | - | 0.01 |
| Biopterin | - | 0.01 |
| Hemin* | 0.0077 | 0.0077 |
| Lipoic acid | - | 0.01 |
| Metals | | |
| CaCl ₂ | - | 0.72 |
| CoCl ₂ | - | 0.000032 |
| CuSO ₄ | - | 0.00003 |
| Fe(NO ₃) ₃ 9H ₂ O | - | 0.009 |
| MnCl ₂ | - | 0.000045 |
| MgSO ₄ 7H ₂ O | - | 0.81 |
| ZnCl ₂ | - | 0.03 |
| Amino Acids | | |
| L-Arginine HCl | 0.5 | 0.5 |
| L-Leucine | 0.5 | 0.5 |
| L-Lysine HCl | 0.5 | 0.5 |
| L-Phenylalanine | 0.5 | 0.5 |
| L-Tryptophan | 0.5 | 0.5 |
| L-Valine | 0.5 | 0.5 |
| L-Alanine | 0.5 | 0.5 |
| L-Asparagine | 0.5 | 0.5 |
| L-Aspartic acid | 0.5 | 0.5 |
| L-Cysteine | 0.5 | 0.5 |
| L-Glutamic acid | 0.5 | 0.5 |
| L-Glutamine | 0.5 | 0.5 |
| Glycine | 0.5 | 0.5 |
| L-Histidine HCl H ₂ O | 0.5 | 0.5 |
| L-Isoleucine | 0.5 | 0.5 |
| L-Methionine | 0.5 | 0.5 |
| L-Proline | 0.5 | 0.5 |
| L-Serine | 0.5 | 0.5 |
| L-Threonine | 0.5 | 0.5 |
| L-Tyrosine | 0.5 | 0.5 |
| Other | | |
| Adenosine | 0.074 | 0.074 |
| Choline chloride | 0.007 | 0.007 |
| D-Glucose | 16.6 | 16.6 |
| HEPES | 25.01 | 25.01 |
| <i>myo</i> -Inositol | 0.01 | 0.01 |
| Sodium pyruvate | 0.99 | 0.99 |

Assessment of amino acid requirements

RE IX medium included the 12 amino acids histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, valine, and glutamine. Arginine, for which *Leishmania* appear to be auxotrophic [13, 14, 41, 42], was not included. To investigate the influence of a complex amino acid content over promastigote growth, we modified the composition of RE IX to include equimolar concentrations (0.5 mM) of all 20 proteogenic amino acids and found that this medium, henceforth referred to as basal medium (BM) (Table 2), significantly enhanced growth of *L. mexicana* promastigotes compared with RE IX (Figure 1A).




Figure 1. Comparison of growth of *L. mexicana* promastigotes in semi-defined serum-supplemented and defined media. A. Growth of *L. mexicana* promastigotes in RE IX medium (black circles), basal medium (BM) (squares), and HOMEM medium (white circles) shown over a 9 day period. B. Growth of *L. mexicana* promastigotes sub-passaged on day 4 in fresh RE IX, BM, and HOMEM media shown over a 9 day period. Abbreviations: BM, basal medium; HOMEM, hemoflagellate-modified minimum essential medium. Error bars = mean \pm standard deviation (SD); n=15.

Assessment of metals and cofactor requirements

As shown by the growth analysis, the BM medium supported robust growth of *L. mexicana* promastigotes (Figure 1A). Nevertheless, there was a pronounced lag phase in the replication rate of freshly passaged cultures, and growth was reduced when cultures were sub-passaged in BM (Figure 1B). We therefore tested the importance of a range of co-factors, vitamins, and metals for promastigote growth. Initial growth analyses (data not included) defined which compounds supported *L. mexicana* promastigote growth and the optimal concentration, and those were consequently used in the requirement analyses. The latter revealed that addition of 10 μ M of biopterin alone or 10 μ M of biopterin, folic acid, lipoic acid, and riboflavin to BM led to a decrease in the time needed by the promastigotes to double in number (Figure 2A). Supplementing BM with magnesium, calcium, zinc, iron, cobalt, copper, and manganese also promoted a significant reduction in the doubling time (Figure 2B). Addition altogether of co-factors, vitamins, and metals to BM further reduced the doubling time of the promastigotes (Figure 2B). Higher concentrations of the seven metals, however, inhibited promastigote growth (data not included).




Figure 2. Effect of co-factors, vitamins, and metals on growth of *L. mexicana* promastigotes. Abbreviations: BM, base medium; HOMEM, hemoflagellate-modified minimum essential medium. Error bars = mean \pm SD; n=15; ****, p<0.0001; ***, p<0.0005, *, p<0.05.

Assessment of promastigote growth in defined Nayak medium

Addition of metals and cofactors to BM resulted in a decrease in the doubling time of *L. mexicana* promastigotes from 30 to 16 h, compared with a doubling time of 12 h in HOMEM. We then tested the ability of the supplemented BM, henceforth referred to as Nayak medium (NM), to support continuous growth of *L. mexicana* promastigotes in sequential passages. We established stable cultures which we were able to maintain for more than 15 sub-passages (Figure 3A). We followed the growth of the promastigotes cultured in NM and HOMEM and observed comparable rates (Figure 3A), although the density of stationary phase promastigotes grown in NM was somewhat lower (data not included). Growth comparison between *L. mexicana*, *L. donovani*, and *L. major* promastigotes additionally revealed that all three species had analogous growth patterns (Figure 3B). Phenotypic comparison between *L. mexicana* promastigotes cultured in NM and HOMEM furthermore showed that log-phase promastigotes grown in NM had shorter body length (Figure 3, C and D) but higher cell volume (data not included) compared with log-phase promastigotes grown in HOMEM, while the opposite, longer body length (Figure 3, C and D) and lower cell volume (data not included), was observed for stationary phase promastigotes grown in NM compared with log-phase promastigotes grown in HOMEM.




Figure 3. Growth and morphometric properties of *Leishmania* promastigotes grown in defined Nayak medium. A. Growth kinetics of *L. mexicana* promastigotes cultured in NM and HOMEM. B. Growth kinetics of *L. donovani* (white squares), *L. mexicana* (black squares), and *L. major* (diamonds) promastigotes cultured in NM. C. Representative images of log phase (day 3) and stationary phase (day 6) *L. mexicana* promastigotes grown in NM and HOMEM. The standard scale bar is 10µm. D. Morphometric comparison of body length of *L. mexicana* promastigotes grown in NM and HOMEM. Abbreviations: NM, Nayak medium; HOMEM, hemoflagellate-modified minimum essential medium; P1, first passage; P2, second passage. Error bars = mean ± SD; n=15.

Assessment of relative importance of specific amino acids

All amino acids in the NM medium were supplemented in free form, allowing to study the importance of each amino acid by individually omitting them from the medium. To assess the relative contribution of each amino acid to the growth of *L. mexicana* promastigotes, we created 20 single amino acid “knock out” media. Our growth assessment showed that omission of phenylalanine and tryptophan halted cell division within 4 h while the absence of arginine, lysine, and leucine resulted in considerably impaired, almost negligible, promastigote growth (Figure 4A). For each of these conditions, no viable cells were observed after 6 days in the respective cultures (data not included). Omission of valine led to very slow growth; absence of aspartate, cysteine, glutamate, glutamine, histidine, isoleucine, methionine, serine, threonine, and tyrosine resulted in an increase in the doubling time; and finally, absence of alanine, asparagine, glycine, and proline imposed no effect over promastigote growth when compared to promastigote growth in NM (Figure 4A).




Figure 4. Single amino acid “knock out” media analysis. A. Growth of *L. mexicana* promastigotes in NM single amino acid “knock out” media, expressed as doubling time. B. Protein content of *L. mexicana* promastigotes grown in single amino acid “knock out” media. C. Comparison of cell size of *L. mexicana* promastigotes grown in single amino acid “knock out” media. Abbreviations: HOMEM, hemoflagellate-modified minimum essential medium; NM, Nayak medium; Gly, glycine; Ala, alanine; Asn, asparagine; Pro, proline; Tyr, tyrosine; Cys, cysteine; Gln, glutamine; Met, methionine; Glu, glutamate; Thr, threonine; Ile, isoleucine; His, histidine; Ser, serine; Asp, aspartate; Val, valine; Leu, leucine; Arg, arginine; Lys, lysine; Phe, phenylalanine; Trp, tryptophan; NM-Trp, Nayak medium without tryptophan; NM-AA, Nayak medium without amino acids. Error bars = mean ± SD; n=9; ****, p<0.0001; ***, p<0.0005, **, p<0.001, *, p<0.05.

Absence of several amino acids is associated with reduced protein synthesis in *Leishmania* [43, 44]. To evaluate the importance of each amino acid for protein synthesis, we maintained *L. mexicana* promastigotes for 6 days in NM single amino acid “knock out” media. As expected, the protein content of promastigotes grown in the same media that did not support cell growth, namely the media without arginine, leucine, lysine, phenylalanine, and tryptophan (Figure 4A), was also dramatically decreased (Figure 4B). More surprising, however, was the observation that the omission of histidine, isoleucine, methionine, and threonine, which only moderately reduced promastigote growth, led to an equally pronounced decrease in protein content (Figure 4B). Reduced protein content suggested that cell size might also be decreased, so we undertook a morphometric analysis of the cells grown in the amino acid “knock out” media. We found a direct correlation between protein content and cell size, namely, that the cells that had lower protein content (Figure 4B) had also dramatically reduced cell size (Figure 4C).

Assessment of promastigote infective competence in defined Nayak medium

The infectivity of *L. mexicana* promastigotes grown in HOMEM and NM was compared *in vitro* by infecting differentiated THP1 macrophages. Intensity and prevalence of infection was similar for both (Figure 5).




Figure 5. Evaluation of infectivity of *L. mexicana* promastigotes in defined Nayak medium. A. Number of amastigotes per 100 macrophages infected with *L. mexicana* promastigotes grown in HOMEM (circles), NM (squares), and heat-killed parasites (triangles). The latter was used as a negative control. B. Percentage of infected macrophages with *L. mexicana* promastigotes grown in HOMEM (white bars) and NM (grey bars), and heat-killed parasites (thick-lined white bars). Abbreviations: NM, Nayak medium; HOMEM, hemoflagellate-modified minimum essential medium. Error bars = mean \pm SD; n=9.

Assessment of promastigote sensitivity to anti-leishmanial drugs

Drug sensitivity of promastigotes grown in HOMEM and NM was compared using the Alamar blue assay [40]. The IC₅₀ measured for methotrexate and pentamidine were significantly lower when cells were grown in NM compared with HOMEM, while the IC₅₀ for amphotericin B was similar under both conditions (Figure 6).




Figure 6. Drug sensitivity of *L. mexicana* promastigotes grown in defined Nayak medium. Toxicity of amphotericin B, pentamidine, and methotrexate on promastigotes grown in HOMEM (white bars) and NM (grey bars) was tested by an Alamar blue assay. Abbreviations: NM, Nayak medium; HOMEM, hemoflagellate-modified minimum essential medium. Error bars = mean \pm SD; n=6; ***, p<0.001.

Discussion

Genomic analysis of *Leishmania* has yielded extensive information about their evolution, distribution, life-cycle, metabolism, and pathogenesis, and has suggested that different species have distinct strategies to cope with the environmental challenges they encounter during development [42, 45 - 49]. However, a recent genomic comparison of several species of *Leishmania* revealed minimal variation in the genome of these organisms [50 - 55]. That suggested that species-specific features are the result of post-transcriptional regulatory mechanisms. The transcriptome, and particularly the proteome and metabolome of *Leishmania*, are highly dynamic and detection of subtle differences in the abundance of components of these systems requires the use of tightly controlled experimental conditions and cutting-edge instrumentation. The use of undefined culture media can confound the interpretation of proteomic and metabolomics datasets, because the proteome or metabolome that is analysed is of mixed origin. The development of defined media could remedy this issue, as well as potentially reduce the cost and the risk of contamination with infectious agents. To facilitate proteomics and metabolomics analysis of *Leishmania*, we have developed a simple, chemically defined growth medium, termed Nayak medium (NM), that supports continuous parasite growth, allows determination of nutrient requirements, and enables proteomics and metabolomics analysis of *Leishmania* to be performed on samples that comprise proteins and metabolites of solely parasite origin.

Leishmania growth in Nayak medium

Comparative growth analyses in NM revealed that *L. mexicana* promastigotes grow at a marginally slower rate and to a lower stationary-phase density but show similar morphology and macrophage infectivity to cells grown in our standard rich, serum-supplemented culture

media (HOMEM). Interestingly, we found that the IC₅₀ for pentamidine and methotrexate was significantly lower in promastigotes grown in NM, compared with HOMEM. We hypothesize that this may be result from interactions between these compounds and serum proteins that are present in HOMEM, and we are currently testing this possibility. Importantly, promastigote growth can be maintained indefinitely in this defined medium, confirming that the latter includes all nutrients required by the organisms, and will permit the generation of large quantities of biological material. Among the medium components in NM, we chose to further investigate amino acid, co-factor, vitamin, and metal requirements.

Amino acids essential for *Leishmania* viability

Arginine, leucine, lysine, phenylalanine, tryptophan, and valine

Amino acids are primary nutrients and as such are acquired or synthesized by organisms. Bioinformatic analysis of *Leishmania* genome sequence datasets suggests they are able to synthesize alanine, aspartate, asparagine, cysteine, glutamate, glutamine, proline, serine, methionine and threonine but must salvage arginine, histidine, isoleucine, leucine, lysine, phenylalanine, tryptophan, tyrosine, and valine from the environment [42]. We tested the importance of each of these substrates for *Leishmania* viability in NM, a background where the only appreciable alternative carbon source was glucose, and were able to confirm that a subset of essential amino acids, namely arginine, leucine, lysine, phenylalanine, tryptophan, and valine (Table 3) are required by *L. mexicana* promastigotes to survive in culture for even a single passage (corresponding to fewer than 5 population doublings). Of these 6 amino acids, transporters only for arginine and lysine have been characterised in *Leishmania* and the respective permeases have been designated AAP3 [41] and AAP7 [56].

Internalised arginine is directed to intermediary metabolism for the synthesis of important biomolecules such as proteins, polyamines, and nitric oxide (Figure 7) [41]. Additionally, a recent metabolomic analysis has revealed that arginine is also converted to citrulline, argininosuccinate (the linking intermediate in the aspartate-to-fumarate interconversion), and argininic acid, and excreted as such by *Leishmania* (Figure 7) [57]. The same study further showed that *L. mexicana* utilizes more arginine compared with *L. major* and *L. donovani* which suggested that the amino acid may have discrete fate and function in the different *Leishmania* sub-species.

Lysine is involved in protein synthesis and is a key site for post-translational modifications (PTMs) of histone and non-histone proteins. Genomic analysis has confirmed that *Leishmania* contain genes for methyltransferases, demethylases, acetyltransferases, and deacetylases [50] and following characterisation of a number of histone acetyltransferase (HAT) genes has suggested that PTMs of lysine play a role in *Leishmania* survival [58 - 61]. No further metabolic function of lysine, however, has been described in *Leishmania*.

Leucine, through 4-methyl-2-oxopentanoate (4mop) and hydroxymethylglutaryl-CoA (HMG-CoA), and valine, through propionyl-CoA and succinyl-CoA, can be converted to acetyl-CoA and then metabolised through the tricarboxylic acid cycle (TCA cycle) (Figure 7) [42]. The products of leucine and valine degradation, namely 4mop and 3-hydroxyisovalerate (HMB),

respectively, are excreted by *Leishmania* [57] while the generated HMG-CoA is used in isoprenoid synthesis [62].

Phenylalanine can be converted to tyrosine, phenyllactate, and phenylpyruvate while tryptophan can be converted to indole 3-lactate, indole 3-pyruvate, indole 3-acetate, and kynurenate, which are all excreted by *Leishmania* (Figure 7) [42, 57]. No intracellular metabolic function has been assigned to these metabolites. It has been proposed, however, that when excreted, the products of aromatic amino acid breakdown are involved in parasite-host interactions and pathogenesis [63, 64].

Table 3. Relative importance of individual amino acids in Nayak defined medium. Amino acid colours correspond to those in Figure 7 and reflect their importance.

| Critical for viability | Support growth | Support protein synthesis | Non-essential (in the presence of glucose) |
|------------------------|----------------|---------------------------|--|
| L-Arginine | L-Aspartate | L-Histidine | L-Alanine |
| L-Leucine | L-Glutamate | L-Isoleucine | L-Asparagine |
| L-Lysine | L-Glutamine | L-Methionine | L-Cysteine |
| L-Phenylalanine | L-Serine | L-Threonine | Glycine |
| L-Tryptophan | | | L-Proline |
| L-Valine | | | L-Tyrosine |




Figure 7. Amino acids shown to be crucial for *Leishmania mexicana* viability in defined Nayak medium. Abbreviations: AAP, amino acid permease; Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartate; Cys, cysteine; Glu, glutamate; Gln, glutamine; Gly, glycine; His, histidine; HMB, 3-hydroxyisovalerate; HMG-CoA, hydroxymethylglutaryl-CoA; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Phe, phenylalanine; Pro, proline; SAM, S-adenosyl-L-methionine; Ser, serine; TCA, tricarboxylic acid cycle; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine.

Amino acids required for growth and protein synthesis in *Leishmania*

The observation that arginine, leucine, lysine, phenylalanine, tryptophan, and valine were crucial for promastigote survival was not surprising, as bioinformatics analyses suggest that *Leishmania* are auxotrophic for these amino acids [42]. They are also predicted to be auxotrophic for isoleucine and histidine, but we observed moderate growth in media lacking these amino acids. However, the protein content and size of these cells was dramatically reduced, suggesting that isoleucine and histidine limitation does impact the cells. It is likely that growth would not be sustained in a subsequent passage into histidine or isoleucine knockout media. The histidine-glutamate pathway does not operate in *Leishmania* and the amino acid thus cannot be used as an energy source [42]. Histidine, instead, serves as a precursor for ovothiol A and as such is proposed to be involved in defence against oxidative stress [65]; a property that may be dispensable in axenic culture but critical in the host. Isoleucine is converted to acetyl-CoA and used in lipid synthesis [66].

Tyrosine can be synthesized from phenylalanine and excreted as 3-(4-hydroxyphenyl)lactate and 4-hydroxyphenyl pyruvate [42, 57]. In 2014, Moreno and colleagues elucidated the crystal structure of *L. infantum* tyrosine aminotransferase (TAT) and showed that TAT is a cytoplasmic enzyme of the I γ subfamily of aminotransferases that is expressed at a higher rate in amastigotes [63, 64]. The latter suggests that tyrosine, similar to other aromatic amino acids whose oxidation end-products have been related to *Leishmania* infectivity in macrophages [63, 64], could be more important, and even vital, for *Leishmania* amastigotes.

Culture of promastigotes in NM that was deficient in lysine resulted in a profound decrease in protein synthesis that was equal to that observed in promastigotes grown without any amino acid. Similarly, omission of methionine and threonine significantly inhibited protein synthesis while that of aspartate and serine slowed, to a great extent, promastigote growth. Aspartate serves as a carbon and energy source and supports asparagine synthesis (Figure 7), TCA cycle anaplerosis, and carbohydrate synthesis via gluconeogenesis [42, 67 - 69]. Serine and methionine are precursors for cysteine (Figure 7) [70] while serine, glycine, and threonine can reversibly be converted into each other by the serine hydroxymethyltransferase (SHMT) and tetrahydrofolate (THF)-dependent glycine cleavage system (GCS) [42]. SHMT and GCS, additionally, are involved in the folic acid biosynthesis pathway whose operation leads to the formation of one-carbon units that are used for the synthesis of thymidylate, purines, and methionine [71, 72]. The latter is a precursor for S-adenosyl-L-methionine (SAM) (Figure 7) which is used in polyamine synthesis [73] and as a methyl donor in various methylation reactions. Cysteine, glycine, and glutamate, in turn, are precursors for glutathione whose conjugation with spermidine leads to the generation of trypanothione, the central antioxidant of trypanosomatids [65]. Serine, additionally, is an important building block in phospho- and sphingolipid biosynthesis while threonine is used for production of acetyl-CoA and acetate (unpublished data). Interestingly, aspartate, glutamate, glutamine and serine, which markedly promote promastigote growth are among the most abundant amino acids in the honeydew on which the insect vectors of *Leishmania* feed [74 - 76].

Of the 20 proteogenic amino acids, only alanine, asparagine, glycine, and proline could be

omitted from NM without significant consequences to promastigote growth. These amino acids can directly be synthesized from pyruvate, aspartate, serine, and glutamate, respectively, and may not be of benefit when the latter substrates are in sufficient quantities.

Alanine plays a key role in osmoregulation [77, 78] and proline, which is a primary carbon and energy source for *L. mexicana* promastigotes when glucose cannot be acquired [67], is not as important under amino acid- and glucose-replete conditions. Metabolism of alanine, asparagine, glycine, and proline might be of greater importance in the gut of the insect vector where energy substrates are variable and osmotic challenges more extreme. In the defined NM medium, however, the four amino acids are non-essential.

Co-factors, vitamins, and metals required for *Leishmania* viability

Previous studies on medium formulation and nutrient requirements and transport have established that *Leishmania* must salvage biotin, pterins, folic acid, pantothenate, pyridoxine, riboflavin, nicotinate, and heme from exogenous sources [10, 33, 42, 72, 79 - 81]. In this study, we showed that biopterin has the highest impact on *in vitro* growth of promastigotes, followed by lipoic acid, folic acid, riboflavin, and *p*-aminobenzoic acid (pABA). *Leishmania* encode multiple genes for folate/biopterin transporters [81 - 84]. When internalised, folic acid is conjugated to pteridine moieties and pABA to form folates which are reduced by pteridine reductase (PTR1) and dihydrofolate reductase–thymidylate synthase (DHFR-TS) and used as co-factors in one-carbon metabolism (Figure 8) [42, 72]. The latter is interweaved with many essential processes, such as the synthesis of thymidylate, methionine, and 10-formyltetrahydrofolate (required for mitochondrial protein synthesis), in *Leishmania* [71, 72, 81]. Folate transport and metabolism, furthermore, have been associated with drug resistance in *Leishmania* [72, 81, 82] and are validated chemotherapeutic targets.

Lipoic acid and its reduced form, dihydrolipoic acids, are highly reactive antioxidants which scavenge reactive oxygen species such as superoxide radicals, hydroxyl radicals, hypochlorous acid, peroxy radicals, singlet oxygen, chromanoxyl radicals of vitamin E, and ascorbyl radicals of vitamin C [85, 86]. Lipoic acid, additionally, is an essential co-factor in several multienzyme complexes, such as pyruvate dehydrogenase (PDH), 2-oxoglutarate dehydrogenase (OGDH), and branched-chain 2-oxo acid dehydrogenase (BCDH) complexes [87]. Similarly, riboflavin, in the form of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), is a co-factor in many flavoproteins which participate in reduction-oxidation reactions, including such leading to energy generation (Figure 8).




Figure 8. Co-factors, vitamins, and metals shown to be important for *Leishmania* growth in defined Nayak medium. Abbreviations: Mg^{2+} , magnesium ion; Ca^{2+} , calcium ion; Fe^{2+} , ferrous ion; Zn^{2+} , zinc ion; Mn^{2+} , manganese ion; Co^{2+} , cobalt ion.

Although we observed growth without specific addition of metals, it is likely that some metal ions are required for growth, and we cannot exclude the possibility that trace amounts of essential metals are added as impurities in other medium components. Nevertheless, we observed that addition of calcium (Ca^{2+}), cobalt (Co^{2+}), copper (Cu^{2+}), iron (Fe^{2+}), manganese (Mn^{2+}), magnesium (Mg^{2+}), and zinc (Zn^{2+}) were important for *Leishmania* growth (Figure 8). Co^{2+} , Cu^{2+} , and Mn^{2+} were effective at much lower concentrations than the other 4 metals. Accordingly, it has been determined that Mg^{2+} , Zn^{2+} , and Fe^{2+} are the most abundant divalent cations in the cytosol of the related organism, *Trypanosoma brucei*, whereas Co^{2+} is present in trace amounts [88]. Two potential CorA-like Mg^{2+} transporters, designated MGT1 and MGT2, have recently been identified in *L. major* and were shown to be important for parasite propagation and infectivity in mice [89]. Mg^{2+} , similar to the other cations discussed here, is an important metal biocatalyst and as such, it has been linked to activation of enzymes such as the *ecto*-ATPase of *L. tropica* which has been implicated in virulence (Figure 8) [90]. Ca^{2+} is stored in acidic compartments termed acidocalcisomes and plays a critical role in signal transduction and host invasion in *Leishmania* [91]. A number of genes encoding putative Ca^{2+} -binding proteins have been identified in the genome of trypanosomatids, and some of these proteins, including protein kinases, peptidases, peroxiredoxins, and ion channels, have been characterised in *Leishmania* [91 - 93]. Metabolically, Ca^{2+} is required for the proper operation of enzymes such as the inorganic pyrophosphatase of *L. major* (Figure 8) [94].

Acquisition of external iron has recently been elucidated and involves the conversion of Fe^{3+} into Fe^{2+} and import of the latter in the *Leishmania* milieu [95]. Fe^{2+} , Zn^{2+} , and Mn^{2+} are components of three well-characterised metalloenzymes of *Leishmania*, namely the antioxidant and virulence factor superoxide dismutase (SOD) [96], the major surface glycoprotein and virulence factor GP63 [97, 98], and arginase [87] (Figure 8). All three enzymes have been associated with host invasion, evasion of host immune response, and establishment of infection [96 - 99]. Mn^{2+} , additionally, is a co-factor for xanthine

phosphoribosyltransferase [100] while Co^{2+} is required by phosphoglycerate mutase [101] (Figure 8).

Although NM was developed as a simple defined medium, our study suggests that many components are not essential for *L. mexicana* growth, as observed for most amino acids. We have tested still more simple media compositions but we observed that growth rates and sustainable growth are reduced as components are removed (data not shown), limiting the use of such minimal media to studies where there is a specific advantage to its use

The development of a defined medium for the axenic culture of amastigotes would be of great use, though this may be more challenging as many of the factors present in animal sera will be relevant to the parasite persistence in the vertebrate host. Accumulating data suggests that amino acids are key substrates throughout the *Leishmania* life-cycle, and our data underscore the relative order of importance of the 20 proteogenic amino acids for parasite growth. Although their phenotypes are very different, exogenous amino acids that are essential to promastigotes are likely essential also in amastigotes, and the routes by which these are acquired and metabolised represent potential drug targets.

Corresponding Author

Richard Burchmore, Richard.Burchmore@glasgow.ac.uk

Tel.: (+44) 141 330 8612

Author Contributions

AN and SA contributed equally to this work. AN contributed to experimental work, data analysis and writing. SA contributed to data analysis and writing. MB contributed to experimental design and writing. RB conceived and directed the study and contributed to data analysis and writing.

Funding Sources

This work was supported by the Doctoral Training Centre (DTC) (Grant number EP/F500424/1) in Technologies at the Interface between Engineering, the Physical Sciences and the Life Sciences, University of Glasgow. The DTC is funded by the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Notes

The authors declare no competing financial interest.

Abbreviations

4mop, 4-methyl-2-oxopentanoate; AAP, amino acid permease; Ala, alanine; ANOVA, Analysis of Variance; Arg, arginine; Asn, asparagine; Asp, aspartate; BCDH, branched-chain 2-oxo acid dehydrogenase; BM, base medium; Ca, calcium; Co, cobalt; Cu, copper; Cys, cysteine; DHFR-TS, dihydrofolate reductase–thymidylate synthase; FAD, flavin adenine dinucleotide; FBT, folate bipterin transporters; FCS, fetal calf serum; Fe, iron; FMN, flavin mononucleotide; GCS, glycine cleavage system; Glu, glutamate; Gln, glutamine; Gly, glycine; HAT, histone acetyltransferase; His, histidine; HMB, 3-hydroxyisovalerate; HMG-CoA, hydroxymethylglutaryl-CoA; HOMEM, hemoflagellate-modified minimum essential medium; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Mg, magnesium; Mn, manganese; NM, Nayak medium; NM-AA, Nayak medium lacking amino acids; OGDH, 2-oxoglutarate dehydrogenase; pABA, *p*-aminobenzoic acid; PBS, phosphate buffered saline; PDH, pyruvate dehydrogenase; PEG, Polyethylene glycol; Phe, phenylalanine; PMA, phorbol 12-myristate 13-acetate; Pro, proline; PTM, post-translational modification; PTR1, pteridine reductase; RT, room temperature; SAM, S-adenosyl-L-methionine; SD, standard deviation; Ser, serine; SOD, superoxide dismutase; TAT, tyrosine aminotransferase; TCA, tricarboxylic acid cycle; THF, tetrahydrofolate; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Val, valine; Zn, zinc.

References

- 1 Morgan, J. F., Morton, H. J., and Parker, R. C. (1950) Nutrition of animal cells in tissue culture; initial studies on a synthetic medium. *Proc Soc Exp Biol Med*, **73**, 1-8
- 2 Dulbecco, R., and Freeman, G. (1959) Plaque production by the polyoma virus. *Virology*, **8**, 396-397
- 3 Moore, G. E., Gerner, R. E., and Franklin, H. A. (1967) Culture of normal human leukocytes. *JAMA*, **199**, 519-524
- 4 Grace, T. D. (1962) Establishment of four strains of cells from insect tissues grown *in vitro*. *Nature*, **195**, 788-789
- 5 Childs, G. E., Foster, K. A., and McRoberts, M. J. (1978) Insect cell culture media for cultivation of New world *Leishmania*. *Int J Parasitol* **8**, 255-258
- 6 Mitsuhashi, J. and Maramorosch, K. (1964) Leafhopper tissue culture: embryonic, nymphal and imaginal tissue from aseptic insects. *Contrib Boyce Thompson Inst*, **22**, 435-460
- 7 Berens, R. L., Brun, R., and Krassner, S. M. (1976) A simple monophasic medium for axenic culture of hemoflagellates. *J Parasitol*, **62**, 360-365
- 8 Schneider, I. (1972) Cell lines derived from late embryonic stages of *Drosophila melanogaster*. *J Embryol Exp Morphol*, **27**, 353-365
- 9 Nicolle, C. (1908) Culture du parasite du bouton d'Orient. *Comptes Rendus de l'Académie des Sciences* **146**, 842-843
- 10 Trager, W. (1957) Nutrition of hemoflagellate (*Leishmania tarentolae*) having a interchangeable requirement for cholin or pyridoxal. *J Protozool*, **4**, 269-276
- 11 Jadin, J. B. and Le Ray, D. (1969) Acquisitions récentes dans les techniques de culture des trypanosomes africains. *Ann Soc belge Méd trop*, **49**, 331-340
- 12 Dwyer, D. M. (1972) A monophasic medium for cultivating *Leishmania donovani* in large numbers. *J Parasitol*, **58**, 847-848
- 13 Steiger, R. F. and Steiger, E. (1976) A defined medium for cultivating *Leishmania donovani* and *L. braziliensis*. *J Parasitol*, **62**, 1010-1011

- 14 Steiger, R. F. and Steiger, E. (1977) Cultivation of *Leishmania donovani* and *Leishmania braziliensis* in defined media: nutritional-requirements. *J Protozool*, **24**, 437-441
- 15 Berens, R. L., and Marr, J. J. (1978) An easily prepared defined medium for cultivation of *Leishmania donovani* promastigotes. *J Parasitol*, **64**,160
- 16 Schuster, F. L. and Sullivan, J. J. (2002) Cultivation of clinically significant hemoflagellates. *Clin Microbiol Rev*, **15**, 374-389
- 17 Palomino, J. C. (1982) Peptone-yeast autolysate-fetal bovine serum 10, a simple, inexpensive liquid medium for the cultivation of *Leishmania* spp. *J Clin Microbiol*, **15**, 949–950
- 18 Sadigursky, M. and Brodskyn, C. I. (1986) A new liquid medium without blood and serum for culture of hemoflagellates. *Am J Trop Med Hyg*, **35**, 942-944
- 19 Armstrong, T. C. and Patterson, J. L. (1994) Cultivation of *Leishmania braziliensis* in an economical serum-free medium containing human urine. *J Parasitol*, **80**, 1030-1032
- 20 Agarwal, M. and Jain, A. (1996) New blood free biphasic medium with haemoglobin for cultivation of *Leishmania donovani* promastigotes. *Indian J Exp Biol*, **34**, 1233-1236
- 21 Limoncu, M. E., Balcioglu, I. C., Yereli, K., Ozbel, Y., and Ozbilgin, A. (1997) A new experimental *in vitro* culture medium for cultivation of *Leishmania* species. *J Clin Microbiol*, **35**, 2430–2431
- 22 Ali, S. A., Iqbal, J., Ahmad, B. and Masoom, M. (1998) A semisynthetic fetal calf serum-free liquid medium for *in vitro* cultivation of *Leishmania* promastigotes. *Am J Trop Med Hyg*, **59**, 163-165
- 23 Singh, S., Mohapatra, D. P., and Sivakumar, R. (2000) Successful replacement of fetal calf serum with human urine for *in vitro* culture of *Leishmania donovani*. *J Commun Dis*, **32**, 289-294
- 24 Meehan, H. A., Lundberg, R. A., and Connell, G. J. (2000) A trypanosomatid protein specifically interacts with a mammalian iron-responsive element. *Parasitol Res*, **86**, 109-114
- 25 Santarem, N., Cunha, J., Silvestre, R., Silva, C., Moreira, D., Ouellette, M., and Cordeiro-Da-Silva, A. (2014) The impact of distinct culture media in *Leishmania infantum* biology and infectivity. *Parasitology*, **141**, 192-205
- 26 Muniaraj, M., Lal, C. S., Kumar, S., Sinha, P. K., and Das, P. (2007) Milk of cow (*Bos taurus*), buffalo (*Bubalus bubalis*), and goat (*Capra hircus*): a better alternative than fetal bovine serum in media for primary isolation, *in vitro* cultivation, and maintenance of *Leishmania donovani* promastigotes. *J Clin Microbiol*, **45**, 1353–1356
- 27 Sharief, A. H., Khalil, E. A. G., Omer, S. A., and Abdalla. H. S. (2008) Innovative serum-free medium for *in vitro* cultivation of promastigote forms of *Leishmania* species. *Parasitol Int*, **57**, 138–142
- 28 Fritsche, C., Sitz, M., Wolf, M., and Pohl, H. D. (2008) Development of a defined medium for heterologous expression in *Leishmania tarentolae*. *J Basic Microbiol*, **48**, 488-95
- 29 Tasew, G., Kebede, A., Wolday, D., Gadisa, E., Britton, S., Eidsmo, L., and Akuffo, H. (2009) Low-cost liquid medium for *in vitro* cultivation of *Leishmania* parasites in low-income countries. *Glob Health Action*, **22**, 2
- 30 Rodrigues, I. de A., da Silva, B. A., dos Santos, A. L., Vermelho, A. B., Alviano, C. S., Dutra, P. M., and Rosa Mdo, S. (2010). A new experimental culture medium for cultivation of *Leishmania amazonensis*: its efficacy for the continuous *in vitro* growth and differentiation of infective promastigote forms. *Parasitol Res*, **106**, 1249–1252
- 31 Grekov, I., Svobodova, M., Nohynkova, E., and Lipoldova, M. (2011). Preparation of highly infective *Leishmania* promastigotes by cultivation on SNB-9 biphasic medium. *J Microbiol Methods*, **87**, 273–277
- 32 Aksoy Gokmen, A., Oncel, K., Ozdemir, O. A., Pektas, B., Cavus, I., Gungor, S., Uzun, B., Kaya, S., Karaca, S., Yula, E., Demirci, M., and Ozbilgin, A. (2015) An alternative

- biphasic nutrient medium for the diagnosis of cutaneous leishmaniasis. *Mikrobiyol Bul*, **49**, 266-271
- 33** Steiger, R. F. and Black, C. D. V. (1980) Simplified defined media for cultivating *Leishmania donovani* promastigotes. *Acta Tropica*, **37**, 195-198
- 34** Melo, N. M., de Azevedo, H. P., Roitman, I., and Mayrink, W. (1985) A new defined medium for cultivating *Leishmania* promastigotes. *Acta Trop*, **42**, 137-41
- 35** O'Daly, J. A. and Rodriguez, M. B. (1988) Differential growth requirements of several *Leishmania* spp. in chemically defined media. *Acta Trop*, **45**, 109-126
- 36** Kar, K., Mukerji, K., Naskar, K., Bhattacharya, A., and Ghosh, D. K. (1990) *Leishmania donovani*: a chemically defined medium suitable for cultivation and cloning of promastigotes and transformation of amastigotes to promastigotes. *Protozoology*, **37**, 277-279
- 37** McCarthy-Burke, C., Bates, P. A., and Dwyer, D. M. (1991) *Leishmania donovani*: use of two different, commercially available, chemically defined media for the continuous *in vitro* cultivation of promastigotes. *Exp Parasitol*, **73**, 385-387
- 38** Merlen, T., Sereno, D., Brajon, N., Rostand, F. and Lemesre, J. L. (1999) *Leishmania* spp.: completely defined medium without serum and macromolecules (CDM/LP) for the continuous *in vitro* cultivation of infective promastigote forms. *Am J Trop Med Hyg*, **60**, 41-50
- 39** Strober, W. (2001) Trypan blue exclusion test of cell viability. *Curr Protoc Immunol*, Appendix 3B
- 40** Raz, B., Iten, M., Grether-Bühler, Y., Kaminsky, R., and Brun, R. (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (*T.b. rhodesiense* and *T.b. gambiense*) *in vitro*. *Acta Trop*, **68**, 139-47
- 41** Shaked-Mishan, P., Suter-Grotemeyer, M., Yoel-Almagor, T., Holland, N., Zilberstein, D., and Rentsch, D. (2006) A novel high-affinity arginine transporter from the human parasitic protozoan *Leishmania donovani*. *Mol Microbiol*, **60**, 30-38
- 42** Opperdoes, F. R. and Coombs, G. H. (2007) Metabolism of *Leishmania*: proven and predicted. *Trends Parasitol*, **23**, 149-158
- 43** Simon, M.W., Jayasimhulu, K., and Mukkada, A.J. (1983) The free amino acid pool in *Leishmania tropica* promastigotes. *Mol Biochem Parasitol* **9**:47-57
- 44** Landfear, S. M. (2011) Nutrient transport and pathogenesis in selected parasitic protozoa. *Eukaryot Cell*, **10**, 483-493
- 45** Burchmore, R. J. S., and Barrett, M. P. (2001) Life in vacuoles - nutrient acquisition by *Leishmania* amastigotes. *Int J Parasitol*, **31**, 1311-1320
- 46** Akhoundi, M., Kuhls, K., Cannet, A., Votýpka, J., Marty, P., Delaunay, P., Sereno, D. (2016) A historical overview of the classification, evolution, and dispersion of *Leishmania* parasites and sandflies. *PLoS Negl Trop Dis*, **10**, e0004349
- 47** Kamhawi, S. (2006) Phlebotomine sand flies and *Leishmania* parasites: friends or foes? *Trends Parasitol*, **22**, 439-445
- 48** Landfear, S. M. (2000) Genetics and biochemistry of *Leishmania* membrane transporters. *Cur Op Microbiol*, **3**, 417-421
- 49** Michels, P. A., Bringaud, F., Herman, M., and Hannaert, V. (2006) Metabolic functions of glycosomes in trypanosomatids. *Biochim Biophys Acta*, **1763**, 1463-1477
- 50** Ivens, A.C., Peacock, C.S., Worthey, E.A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M.A., Adlem, E., Aert R., Anupama, A., Apostolou, Z., Attipoe, P., Bason, N., Bauser, C., Beck, A., Beverley, S.M., Bianchetin, G., Borzym, K., Bothe, G., Bruschi, C.V., Collins, M., Cadag, E., Ciarloni, L., Clayton, C., Coulson, R.M., Cronin, A., Cruz, A.K., Davies, R.M., De Gaudenzi, J., Dobson, D.E., Duesterhoeft, A., Fazelina, G., Fosker, N., Frasch, A.C., Fraser, A., Fuchs, M., Gabel, C., Goble, A., Goffeau, A., Harris, D., Hertz-Fowler, C., Hilbert, H., Horn, D., Huang, Y., Klages, S., Knights, A., Kube, M., Larke,

N., Litvin, L., Lord, A., Louie, T., Marra, M., Masuy, D., Matthews, K., Michaeli, S., Mottram, J.C., Müller-Auer, S., Munden, H., Nelson, S., Norbertczak, H., Oliver, K., O'Neil, S., Pentony, M., Pohl, T.M., Price, C., Purnelle, B., Quail, M.A., Rabbinowitsch, E., Reinhardt, R., Rieger, M., Rinta, J., Robben, J., Robertson, L., Ruiz, J.C., Rutter, S., Saunders, D., Schäfer, M., Schein, J., Schwartz, D.C., Seeger, K., Seyler, A., Sharp, S., Shin, H., Sivam, D., Squares, R., Squares, S., Tosato, V., Vogt, C., Volckaert, G., Wambutt, R., Warren, T., Wedler, H., Woodward, J., Zhou, S., Zimmermann, W., Smith, D.F., Blackwell, J.M., Stuart, K.D., Barrell, B., and Myler, P.J. (2005) The genome of the kinetoplastid parasite, *Leishmania major*. *Science* 309:436–442

51 Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., Bartholomeu, D. C., Lennard, N. J., Caler, E., Hamlin, N. E., Haas, B., Bohme, U., Hannick, L., Aslett, M. A., Shallom, J., Marcello, L., Hou, L., Wickstead, B., Alsmark, U. C., Arrowsmith, C., Atkin, R. J., Barron, A. J., Bringaud, F., Brooks, K., Carrington, M., Chrevach, I., Chillingworth, T. J., Churcher, C., Clark, L. N., Corton, C. H., Cronin, A., Davies, R. M., Doggett, J., Djikeng, A., Feldbyum, T., Field, M. C., Fraser, A., Goodhead, I., Hance, Z., Harper, D., Harris, B. R., Hauser, H., Hostetler, J., Ivens, A., Jagels, K., Johnon, D., Johnson, J., Jones, K., Kerhornou, A. X., Koo, H., Larke, N., Landfear, S., Larkin, C., Leech, V., Line, A., Lord, A., Maclod, A., Mooney, P.J., Moul, S., Martin, D.M., Morgan, g.W., Mungall, K., Norbertczak, H., Ormond, D., Pai, G., Peacock, C. S., Peterson, J., Quail, M. A., Rabbinowitsch, E., Rajandream, M.A., Reitter, C., Salzberg, S. L., Sanders, M., Schobel, M., Sharp, S., Simmonds, M., Simpson, A. J., Tallon, L., Turner, C. M., Tait, A., Tivey, A. R., van Aken, S., Walker, D., Wanless, D., Wang, S., White, B., White, O., Whitehead, S., Woodward, J., Wortman, J., Adams, M. D., Embley, T. M., Gull, K., Ullu, E., Barry, J. D., Fairlamb, A. H., Opperdoes, F., Barrell, B. G., Donelson, J. E., Hall N., Fraser, C. M., Melville, S. E., and El-Sayed, N. M. (2005) The genome of the African trypanosome *Trypanosoma brucei*. *Science*, **309**, 416-422

52 Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters, N., Adlem, E., Tivey, A., Aslett, M., Kerhornou, A., Ivens, A., Fraser, A., Rajandream, M.-A., Carver, T., Norbertczak, H., Chillingworth, T., Hance, Z., Jagels, K., Moule, S., Ormond, D., Rutter, S., Squares, R., Whitehead, S., Rabbinowitsch, E., Arrowsmith, C., White, B., Thurston, S., Bringaud, F., Baldauf, S. L., Falconbridge, A., Jeffares, D., Depledge, D. P., Oyola, S. O., Hilley, J. D., Brito, L. O., Tosi, L. R. O., Barrell, B., Cruz, A. K., Mottram, J. C., Smith, D. F., and Berriman, M. (2007) Comparative genomic analysis of three *Leishmania* species that cause diverse human disease. *Nat Genet*, **39**, 839–847

53 Rogers, M. B., Hilley, J. D., Dickens, N. J., Wilkes, J., Bates, P. A., Depledge, D. P., Harris, D., Her, Y., Herzyk, P., Imamura, H., Otto, T. D., Sanders, M., Seeger, K., Dujardin, J.-C., Berriman, M., Smith, D. F., Hertz-Fowler, C., and Mottram, J. C., (2011) Chromosome and gene copy number variation allow major structural change between species and strains of *Leishmania*. *Genome Res*, **21**, 2129–2142

54 Downing, T., Stark, O., Vanaerschot, M., Imamura, H., Sanders, M., Decuypere, S., de Doncker, S., Maes, I., Rijal, S., Sundar, S., Dujardin, J.-C., Berriman, M., and Schönian, G. (2012) Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the *Leishmania donovani* species complex. *Infect Genet Evol*, **12**, 149–159

55 Downing, T., Imamura, H., Decuypere, S., Clark, T. G., Coombs, G. H., Cotton, J. A., Hilley, J. D., de Doncker, S., Maes, I., Mottram, J. C., Quail, M. A., Rijal, S., Sanders, M., Schönian, G., Stark, O., Sundar, S., Vanaerschot, M., Hertz-Fowler, C., Dujardin, J.-C., and Berriman, M (2011) Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure and mechanisms of drug resistance. *Genome Res*, **21**, 2143–2156

- 56** Inbar, E., Canepa, G. E., Carrillo, C., Glaser, F., Suter Grotemeyer, M., Rentsch, D., Zilberstein, D., and Pereira, C. A. (2012) Lysine transporters in human trypanosomatid pathogens. *Amino Acids*, **42**, 347-360
- 57** Westrop, G. D., Williams, R. A. M., Wang, L., Zhang, T., Watson, D. G., Silva, A. M., and Coombs, G. H. (2015) Metabolomic analyses of *Leishmania* reveal multiple species differences and large differences in amino acid metabolism. *PLoS ONE*, **10**, e0136891
- 58** Maity, A. K., and Saha, P. (2012) The histone acetyl transferase LdHAT1 from *Leishmania donovani* is regulated by S-phase cell cycle kinase. *FEMS Microbiol Lett*, **336**, 57-63
- 59** Jha, P. K., Khan, M. I., Mishra, A., Das, P., and Sinha, K. K. (2017) HAT2 mediates histone H4K4 acetylation and affects micrococcal nuclease sensitivity of chromatin in *Leishmania donovani*. *PLoS ONE* **12**, e0177372
- 60** Kumar, D., and Saha, S. (2015) HAT3-mediated acetylation of PCNA precedes PCNA monoubiquitination following exposure to UV radiation in *Leishmania donovani*. *Nucleic Acids Res*, **43**, 5423-5441
- 61** Yadav, A., Chandra, U., and Saha, S. (2016) Histone acetyltransferase HAT4 modulates navigation across G2/M and re-entry into G1 in *Leishmania donovani*. *Sci Rep*, **6**, 27510
- 62** Ginger, M. L., Chance, M. L., Sadler, I. H., and Goad, L. J. (2001) The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid *Leishmania mexicana*. *J Biol Chem*, **276**, 11674-11682
- 63** Moreno, M. A., Abramov, A., Abendroth, J., Alonso, A., Zhang, S., Alcolea, P. J., Edwards, T., Lorimer, D., Myler, P. J., and Larraga, V. (2014) Structure of tyrosine aminotransferase from *Leishmania infantum*. *Acta Crystallogr F Struct Biol Commun*, **70**, 583-587
- 64** Moreno, M. A., Alonso, A., Alcolea, P. J., Abramov, A., de Lacoba, M. G., Abendroth, J., Zhang, S., Edwards, T., Lorimer, D., Myler, P. J., and Larraga, V. (2014) Tyrosine aminotransferase from *Leishmania infantum*: A new drug target candidate. *Int J Parasitol Drugs Drug Resist*, **4**, 347-354
- 65** Steenkamp, D. J. (2002) Thiol metabolism of the trypanosomatids as potential drug targets. *IUBMB Life*, **53**, 243-248
- 66** Ginger, M. L., Chance, M. L., and Goad, L. J. (1999) Elucidation of carbon sources used for the biosynthesis of fatty acids and sterols in the trypanosomatid *Leishmania mexicana*. *Biochem J*, **342**, 397-405
- 67** Akpunarlieva, S., Weidt, S., Lamasudin, D., Naula, C., Henderson, D., Barrett, M., Burgess, K., and Burchmore, R. (2017) Integration of proteomics and metabolomics to elucidate metabolic adaptation in *Leishmania*. *J Proteomics*, **155**, 85-98
- 68** Rodriguez-Contreras, D. and Landfear, S.M. (2006) Metabolic changes in glucose transporter-deficient *Leishmania mexicana* and parasite virulence. *J Biol Chem*, **281**, 20068-20076
- 69** Rodriguez-Contreras, D. and Hamilton, N. (2014) Gluconeogenesis in *Leishmania mexicana*: contribution of glycerol kinase, phosphoenolpyruvate carboxykinase, and pyruvate phosphate dikinase. *J Biol Chem*, **289**, 32989-33000
- 70** Williams, R.A., Westrop, G.D., and Coombs, G.H. (2009) Two pathways for cysteine biosynthesis in *Leishmania major*. *Biochem J*, **420**, 451-462
- 71** Muller, M. and Papadopoulou, B. (2010) Stage-specific expression of the glycine cleavage complex subunits in *Leishmania infantum*. *Mol Biochem Parasitol*, **170**, 17-27
- 72** Ouellette, M., Drummel-Smith, J., El-Fadili, A., Kundig, C., Richard, D., and Roy, G. (2002) Pterin transport and metabolism in *Leishmania* and related trypanosomatid parasites. *Int J Parasitol*, **32**, 385-398

- 73** Colotti, G. and Ilari, A. (2011) Polyamine metabolism in *Leishmania*: from arginine to trypanothione. *Amino Acids*, **40**, 269-285
- 74** Byrne, D. N. and Miller, W. B. (1990) Carbohydrate and amino acid composition of phloem sap and honeydew produced by *Bemisia tabaci*. *J Insect Physiol*, **36**, 433-439
- 75** Sandstrom, J.P. and Moran, N.A. (2001) Amino acid budgets in three aphid species using the same host plant. *Physiol Entomol*, **26**, 202-211
- 76** Crafts-Brandner, S.J. (2002) Plant nitrogen status rapidly alters amino acid metabolism and excretion in *Bemisia tabaci*. *J Insect Physiol*, **48**, 33-41
- 77** Darling, T. N., Burrows, C. M., and Blum, J. J. (1990) Rapid shape change and release of ninhydrin-positive substances by *Leishmania major* promastigotes in response to hypo-osmotic stress. *J Protozool*, **37**, 493-499
- 78** Burrows, C. and Blum, J.J. (1991) Effect of hyper-osmotic stress on alanine content of *Leishmania major* promastigotes. *J Protozool*, **38**, 47-52
- 79** Chang, C. S. and Chang, K. P. (1985) Heme requirement and acquisition by extracellular and intracellular stages of *Leishmania mexicana amazonensis*. *Mol Biochem Parasitol*, **16**, 267-276
- 80** Beck, J. T. and Ullman, B. (1990) Nutritional requirements of wild-type and folate transport-deficient *Leishmania donovani* for pterins and folates. *Mol Biochem Parasitol*, **43**, 221-230
- 81** Cunningham, M. L. and Beverley, S. M. (2001) Pteridine salvage throughout the *Leishmania* infectious cycle: implications for antifolate chemotherapy. *Mol Biochem Parasitol*, **113**, 199-213
- 82** Lemley, C., Yan, S., Dole, V. S., Madhubala, R., Cunningham, M. L., Beverley, S. M., Myler, P. J., and Stuart, K. D. The *Leishmania donovani* LD1 locus gene ORFG encodes a biopterin transporter (BT1). *Mol Biochem Parasitol* 1999, 104:93-105
- 83** Richard, D., Leprohon, P., Drummel-Smith, J., and Ouellette, M. Growth phase regulation of the main folate transporter of *Leishmania infantum* and its role in methotrexate resistance. *J Biol Chem* 2004, 279:54494-54501
- 84** Richard, D., Kündig, C., and Ouellette, M. (2002) A new type of high affinity folic acid transporter in the protozoan parasite *Leishmania* and deletion of its gene in methotrexate-resistant cells. *J Biol Chem*, **277**, 29460-29467
- 85** Datta, G. and Bera, T. (2001) Evidence for the extracellular reduction of alpha-lipoic acid by *Leishmania donovani* promastigotes: a transplasma membrane redox system. *Biochim Biophys Acta*, **1512**, 149-157
- 86** Kagan, V. E., Shvedova, A., Serbinova, E., Khan, S., Swanson, C., Powell, R., and Packer L. (1992) Dihydrolipoic acid--a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxy, ascorbyl and chromanoxyl radicals. *Biochem Pharmacol*, **44**, 1637-1649
- 87** Perham, R. N. (2000) Swinging arms and swinging domains in multifunctional enzymes: catalytic machines for multistep reactions. *Annu Rev Biochem*, **69**, 961-1004
- 88** Fuad, F. A., Fothergill-Gilmore, L. A., Nowicki, M. W., Eades, L. J., Morgan, H. P., McNae, I. W., Michels, P. A., and Walkinshaw, M. D. (2011) Phosphoglycerate mutase from *Trypanosoma brucei* is hyperactivated by cobalt *in vitro*, but not *in vivo*. *Metallomics*, **3**, 1310-1317
- 89** Zhu, Y., Davis, A., Smith, B. J., Curtis, J., and Handman, E. (2009) *Leishmania major* CorA-like magnesium transporters play a critical role in parasite development and virulence. *Int J Parasitol*, **39**, 713-723
- 90** Berrêdo-Pinho, M., Peres-Sampaio, C. E., Chrispim, P. P., Belmont-Firpo, R., Lemos, A. P., Martiny, A., Vannier-Santos, M. A., and Meyer-Fernandes, J. R. (2015) A Mg-dependent

- ecto-ATPase in *Leishmania amazonensis* and its possible role in adenosine acquisition and virulence. *Arch Biochem Biophys*, **391**, 16-24
- 91** Docampo, R. and Huang, G. (2015) Calcium signaling in trypanosomatid parasites. *Cell Calcium*, **57**, 194-202
- 92** Dey, R., Bhattacharya, J., and Datta, S. C. (2006) Calcium-dependent proteolytic activity of a cysteine protease caldonopain is detected during *Leishmania infection*. *Mol Cell Biochem*, **281**, 27-33
- 93** Morais, M. A. B., Giuseppe, P. O., Souza, T. A. C. B., Castro, H., Honorato, R. V., Oliveira, P. S. L., Netto, L. E. S., Tomas, A. M., and Murakami M. T. (2017) Calcium and magnesium ions modulate the oligomeric state and function of mitochondrial 2-Cys peroxiredoxins in *Leishmania* parasites. *J Biol Chem*, **292**, 7023-7039
- 94** Gomez-Garcia, M. R., Ruiz-Perez, L. M., Gonzalez-Pacanowska, D., and Serrano, A. (2004) A novel calcium-dependent soluble inorganic pyrophosphatase from the trypanosomatid *Leishmania major*. *FEBS Letters*, **560**, 158-166
- 95** Andrew R. Flannery, A. R., Renberg, R. L., and Andrews, N. W. (2013) Pathways of iron acquisition and utilization in *Leishmania*. *Curr Opin Microbiol*, **16**, 716-721
- 96** Mitra, B., Laranjeira-Silva, M. F., Miguel, D. C., Perrone Bezerra de Menezes, J., Andrews N. W. (2017) The iron-dependent mitochondrial superoxide dismutase SODA promotes *Leishmania* virulence. *J Biol Chem*, **292**, 12324-12338
- 97** Schlagenhauf, E., Etges, R., and Metcalf, P. (1998) The crystal structure of the *Leishmania major* surface proteinase leishmanolysin (gp63). *Structure*, **6**, 1035-1046
- 98** Joshi, P. B., Kelly, B. L., Kamhawi, S., Sacks, D. L., and McMaster, W. R. (2002) Targeted gene deletion in *Leishmania major* identifies leishmanolysin (GP63) as a virulence factor. *Mol Biochem Parasitol*, **120**, 33-40
- 99** da Silva, E. R., da Silva, M. F. L., Fischer, H., Mortara, R. A., Mayer, M. G., Framesqui, K., Silber, A. M., and Floeter-Winte, L. M. (2008) Biochemical and biophysical properties of a highly active recombinant arginase from *Leishmania (Leishmania) amazonensis* and subcellular localization of native enzyme. *Mol Biochem Parasitol*, **159**, 104-111
- 100** Kidder, G. W. and Nolan, L. L. (1982) Xanthine phosphoribosyltransferase in *Leishmania*: divalent cation activation. *J Protozool*, **29**, 405-409
- 101** Nowicki, M. W., Kuaprasert, B., McNae, I. W., Morgan, H. P., Harding, M. M., Michels, P. A., Fothergill-Gilmore, L. A., and Walkinshaw, M. D. (2009) Crystal structures of *Leishmania mexicana* phosphoglycerate mutase suggest a one-metal mechanism and a new enzyme subclass. *J Mol Biol*, **394**, 535-543